First in the World to Enroll in Lung Cancer Trial
Researchers at the Harry and Jeanette Weinberg Cancer Institute at MedStar Franklin Square Medical Center have enrolled the first patient in the world in a Phase III study of treatment for lung cancer.
Estimated enrollment for “A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)” will be approximately 560 patients from around the world. These patients will be treated over three years. This study is sponsored by Merck Sharp & Dohme and is being conducted at MedStar Franklin Square Medical Center and MedStar Union Memorial Hospital, both located in Baltimore.
This enrollment is a testament to the coordinated care that patients receive from the entire team, including Suman Rao, MD, and Kevin Chen, MD. front-line associates, pharmacy, and administrative and clinical research staff.
“I have seen the difficulties that other sites face trying to get studies started and patients scheduled to fit protocol requirements and I know that our site does a phenomenal job coordinating care,” said Jean M. Flack, BSN, OCN, CCRC, manager, Oncology Research at MedStar Baltimore Oncology Network. “Everyone does a superb job helping us with our research patients.”